Details of the BTS | SYNBIP

General Information of Binding Target of SBP (BTS) (ID: ST00259)
BTS Name	Complement C5
Synonyms	C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4
BTS Type	Protein
Gene Name	C5
Organism	Homo sapiens (Human)
Function	Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.; Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.
UniProt ID	P01031
UniProt Entry	CO5_HUMAN
PFam	PF00207 ; PF07703 ; PF07677 ; PF01821 ; PF17790 ; PF01835 ; PF17791 ; PF17789 ; PF01759 ; PF07678
Gene ID	727
Sequence	MGLLGILCFLIFLGKTWGQEQTYVISAPKIFRVGASENIVIQVYGYTEAFDATISIKSYP DKKFSYSSGHVHLSSENKFQNSAILTIQPKQLPGGQNPVSYVYLEVVSKHFSKSKRMPIT YDNGFLFIHTDKPVYTPDQSVKVRVYSLNDDLKPAKRETVLTFIDPEGSEVDMVEEIDHI GIISFPDFKIPSNPRYGMWTIKAKYKEDFSTTGTAYFEVKEYVLPHFSVSIEPEYNFIGY KNFKNFEITIKARYFYNKVVTEADVYITFGIREDLKDDQKEMMQTAMQNTMLINGIAQVT FDSETAVKELSYYSLEDLNNKYLYIAVTVIESTGGFSEEAEIPGIKYVLSPYKLNLVATP LFLKPGIPYPIKVQVKDSLDQLVGGVPVTLNAQTIDVNQETSDLDPSKSVTRVDDGVASF VLNLPSGVTVLEFNVKTDAPDLPEENQAREGYRAIAYSSLSQSYLYIDWTDNHKALLVGE HLNIIVTPKSPYIDKITHYNYLILSKGKIIHFGTREKFSDASYQSINIPVTQNMVPSSRL LVYYIVTGEQTAELVSDSVWLNIEEKCGNQLQVHLSPDADAYSPGQTVSLNMATGMDSWV ALAAVDSAVYGVQRGAKKPLERVFQFLEKSDLGCGAGGGLNNANVFHLAGLTFLTNANAD DSQENDEPCKEILRPRRTLQKKIEEIAAKYKHSVVKKCCYDGACVNNDETCEQRAARISL GPRCIKAFTECCVVASQLRANISHKDMQLGRLHMKTLLPVSKPEIRSYFPESWLWEVHLV PRRKQLQFALPDSLTTWEIQGVGISNTGICVADTVKAKVFKDVFLEMNIPYSVVRGEQIQ LKGTVYNYRTSGMQFCVKMSAVEGICTSESPVIDHQGTKSSKCVRQKVEGSSSHLVTFTV LPLEIGLHNINFSLETWFGKEILVKTLRVVPEGVKRESYSGVTLDPRGIYGTISRRKEFP YRIPLDLVPKTEIKRILSVKGLLVGEILSAVLSQEGINILTHLPKGSAEAELMSVVPVFY VFHYLETGNHWNIFHSDPLIEKQKLKKKLKEGMLSIMSYRNADYSYSVWKGGSASTWLTA FALRVLGQVNKYVEQNQNSICNSLLWLVENYQLDNGSFKENSQYQPIKLQGTLPVEAREN SLYLTAFTVIGIRKAFDICPLVKIDTALIKADNFLLENTLPAQSTFTLAISAYALSLGDK THPQFRSIVSALKREALVKGNPPIYRFWKDNLQHKDSSVPNTGTARMVETTAYALLTSLN LKDINYVNPVIKWLSEEQRYGGGFYSTQDTINAIEGLTEYSLLVKQLRLSMDIDVSYKHK GALHNYKMTDKNFLGRPVEVLLNDDLIVSTGFGSGLATVHVTTVVHKTSTSEEVCSFYLK IDTQDIEASHYRGYGNSDYKRIVACASYKPSREESSSGSSHAVMDISLPTGISANEEDLK ALVEGVDQLFTDYQIKDGHVILQLNSIPSSDFLCVRFRIFELFEVGFLSPATFTVYEYHR PDKQCTMFYSTSNIKIQKVCEGAACKCVEADCGQMQEELDLTISAETRKQTACKPEIAYA YKVSITSITVENVFVKYKATLLDIYKTGEAVAEKDSEITFIKKVTCTNAELVKGRQYLIM GKEALQIKYNFSFRYIYPLDSLTWIEYWPRDTTCSSCQAFLANLDEFAEDIFLNGC
Sequence Length	1676

Synthetic Binding Protein (SBP) Targeting This BTS

SBP Name	Highest Status	Mechanism	Affinity	Application	Details	Ref
Macrocyclic peptide anti-C5 RA-101295	Research	Inhibitor	N.A.	Sepsis [ICD-11: 1G40-1G41]	SBP Info	[1]
Macrocyclic peptide anti-C5 RA-101348	Research	Inhibitor	N.A.	Haemolytic uraemic syndrome [ICD-11: 3A21.2]; Lupus nephritis [ICD-11: 4A40.0Y]; Motor neurone disease [ICD-11: 8B60.Z]; Myasthenia gravis [ICD-11: 8C60.Z]; Cardiomyopathy [ICD-11: BC43]; Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0]; Renal failure [ICD-11: GB6Z]	SBP Info	[2]
Macrocyclic peptide Zilucoplan	Phase III	Inhibitor	N.A.	Myasthenia gravis [ICD-11: 8C60.Z]	SBP Info	[3], [4]
Nanobody anti-E2 glycoprotein UNbC5-1	Research	Inhibitor	Kd: 0.1199 nM	Tools as diagnostic and/or research tools to detect C5 or inhibit C5 cleavage	SBP Info	[5]
Nanobody anti-E2 glycoprotein UNbC5-2	Research	Inhibitor	Kd: 0.0077 nM	Tools as diagnostic and/or research tools to detect C5 or inhibit C5 cleavage	SBP Info	[5]
Repebody anti-Anaphylatoxin-C5a r-3E8	Research	Inhibitor	Kd: 5 nM	C5a-involved inflammatory diseases	SBP Info	[6]

References

1	Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model of Escherichia coli sepsis. Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):E6390-E6399.
2	Generation of complement molecular complex C5b-9 (C5b-9) in response to poly-traumatic hemorrhagic shock and evaluation of C5 cleavage inhibitors in non-human primates. Int Immunopharmacol. 2018 Jan;54:221-225.
3	ClinicalTrials.gov (NCT04436497) HEALEY ALS Platform Trial - Regimen A Zilucoplan
4	ClinicalTrials.gov (NCT04225871) Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
5	Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodies. J Biol Chem. 2023 Aug;299(8):104956.
6	Effective suppression of C5a-induced proinflammatory response using anti-human C5a repebody. Biochem Biophys Res Commun. 2016 Sep 2;477(4):1072-1077.